Last reviewed · How we verify
CoronaVac Biofarma COVID-19 Vaccine
CoronaVac is an inactivated whole-virus COVID-19 vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2.
CoronaVac is an inactivated whole-virus COVID-19 vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2. Used for COVID-19 prevention in adults.
At a glance
| Generic name | CoronaVac Biofarma COVID-19 Vaccine |
|---|---|
| Sponsor | Dr. Soetomo General Hospital |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated SARS-CoV-2 virus particles that cannot cause infection but retain antigenic properties. When administered, these particles trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live virus upon exposure. This approach has been used successfully in other viral vaccines such as polio and hepatitis A.
Approved indications
- COVID-19 prevention in adults
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) (EARLY_PHASE1)
- UNAIR Inactivated COVID-19 Vaccine (PHASE1, PHASE2)
- UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoronaVac Biofarma COVID-19 Vaccine CI brief — competitive landscape report
- CoronaVac Biofarma COVID-19 Vaccine updates RSS · CI watch RSS
- Dr. Soetomo General Hospital portfolio CI